Small effects of smoking on visual spatiotemporal processing

Altered functional connectivity within the primary visual networks and neurotransmitter activity in male smokers: A group ICA study

Smoking puts patients at high risk for cognitive and psychiatric disorders. The aim of this study was to explore the effects of nicotine use on primary visual network (PVN) and its association with neurotransmitters. A total of 59 tobacco use disorder (TUD) patients and 51 healthy controls (HC) participated in this study and underwent resting state functional magnetic resonance imaging scans. Functional connectivity (FC) within the network was explored using independent component analysis. In addition, the spatial correlations of PVN changes with neurotransmitters and their correlations with clinical characteristics of patients were evaluated using the JuSpace toolbox and SPSS. We found reduced FC within the PVN in patients with TUD compared with HC. In terms of relevant analysis, there is a spatial correlation between FC changes in the patient's PVN and a higher distribution of dopamine receptor and gamma-aminobutyric acid receptor. This study revealed changes in the FC and neurotransmitters of the PVN in patients with TUD, expanding the potential neural mechanisms underlying sensory perception and psychiatric disorders.

Impairments of facial detection in tobacco use disorder: baseline data and impact of smoking duration

Objective:

Chronic tobacco consumption, classified as tobacco use disorder (TUD), has been associated with a variety of health problems. Investigations of face processing in TUD are hampered by lack of evidence. Here, we evaluated facial detection in TUD and assessed test-retest reliability for a facial detection task.

Methods:

Participants were instructed to detect the orientation (either left or right) of a face when it was presented with a face/non-face pair on the monitor screen, using Bayesian entropy estimation. Bland-Altman analysis and intraclass correlation coefficients were used to test the reliability of the task. The general linear model and Bayesian statistics were then used to evaluate differences between TUD (n=48) and healthy controls (n=34).

Results:

The reliability of the task was high for the 96 stimuli presentations. Slower reaction times (p < 0.001) and lower discrimination index (p < 0.001) were observed in the TUD group than for healthy controls. Mediation analysis indicated direct effects of smoking duration on reaction time (p < 0.001) and discrimination index (p < 0.001).

Conclusions:

Overall, we observed high reliability of this task and reduction of facial detection in tobacco use disorder. We conclude our findings are significant for public health initiatives and call for follow-up studies.

Nicotine gum enhances visual processing in healthy nonsmokers

OBJECTIVE

The main purpose of this study was to investigate the isolated effects of nicotine on visual processing, namely contrast processing.

METHODS

Thirteen participants, aged 18-40 years, were enrolled in this double blind, randomized and pilot controlled trial involving nicotine gum administration (placebo, 2-mg and 4-mg doses). The participants' instruction was to detect the location of vertical gratings (0.2; 1.0; 3.3; 5.7; 8.8; 13.2 and 15.9 cycles per degree) when it was presented either left or right on the monitor screen. A repeated multivariate analysis of variance was conducted to analyse the results for the visual processing tasks. Bayesian analyses were also carried out considering maximum robustness to avoid bias.

RESULTS

The findings that nicotine gum administration resulted in better contrast discrimination when compared to placebo gum (p < .001). More specifically, the 4-mg resulted in better visual sensitivity when compared to the 2-mg (p < .01) and the placebo (p < .001) gum. Demographic data were not related to the outcomes.

CONCLUSIONS

These data bring the need for support the findings. If proved, it is possible that nicotine, in small doses, can have a potential therapeutic use for those populations with low vision.

TRIAL REGISTRATION NUMBER

RBR-46tjy3.

Effects of Nicotine Gum Administration on Vision (ENIGMA-Vis): Study Protocol of a Double-Blind, Randomized, and Controlled Clinical Trial

Studies reported that tobacco addiction was related to visual impairments, but one unresolved issue is whether the impairments are related to the many compounds existing in the cigarettes or to the effects of nicotine. On the other hand, nicotine gum can be used as replacement therapy or as a neuroprotective agent for some diseases. The main purpose of this controlled trial is to investigate the effects of nicotine gum on vision. The ENIGMA-Vis trial aims to compare two dosages of nicotine gum (2 and 4 mg) and a placebo gum in a randomized, double-blind, placebo-controlled trial of 100 participants to be allocated into a single group assignment of repeated measures (two studies; N = 50 for each one). Eligibility criteria are healthy non-smokers not diagnosed with substance abuse and without an acute or chronic medical condition. Intervention will last three sessions for each participant with a window frame of 1 week per session. Study outcomes are (1) short-term effects of nicotine gum on contrast sensitivity; (2) short-term effects of nicotine gum on chromatic contrast discrimination; and (3) whether demographics, body mass index, or serum cotinine predicts response of visual processing. This study addresses an important gap in the effects of nicotine on vision. One of the main takeaways of this study is to understand the effects of nicotine on contrast sensitivity and chromatic contrast discrimination. This information will provide a further understanding of how nicotine interacts with early visual processes and help determine how the different components present during smoking can affect vision.

Clinical Trial Registration Number: RBR-46tjy3.

Visual impairments in tobacco use disorder

Prior studies found small effects of chronic smoking on spatial and color vision, but they were inconclusive. This study tries to: (1) replicate and extend these previous findings, and (2) rule in that this relationship is pronounced by tobacco addiction. Data were recorded in 71 healthy controls (M = 33.5 years; SD = 5.4 years) and 63 individuals with tobacco addiction (M = 34.7 years; SD = 4.8 years). Visual processing was assessed in the forms of contrast sensitivity for linear sine-wave gratings (spatial frequencies ranging between 0.2 and 16 cycles per degree) and color discrimination (using the Ellipse and Trivector subtests). The groups were matched for age, gender and level of education. The group with heavy smokers had reduced sensitivity for all spatial frequencies (p < .001), and impairments in color discrimination for both Trivector (all p-values < .001 for Protan, Deutan and Tritan) and Ellipse (all p-values < .001). This study consistently replicates and extended previous findings, and showed that visual processing can be strongly associated with tobacco addiction. These results indicate that excessive use of cigarettes, or chronic exposure to their compounds, affects visual discrimination, supporting the existence of overall deficits in visual processing in tobacco addiction.

Tobacco Use Decreases Visual Sensitivity in Schizophrenia

Smoking prevalence in patients who are diagnosed with schizophrenia (SCZ) is higher than in the general population. Chronic tobacco use in SCZ patients may reduce the side effects of antipsychotic drugs, thus serving as a self-medication for such side effects. Understanding the ways in which chronic tobacco use influences visual sensitivity has clinical implications, which may serve as a tool for non-invasively diagnosing early-stage visual processing deficits. The present study evaluated the effects of chronic tobacco use on visual sensitivity in SCZ patients. Our purpose was to provide new directions for future research, mainly psychophysical and electrophysiological studies. In the present study, 40 smoker controls (SC), 20 SCZ tobacco users, and 20 SCZ tobacco nonusers were recruited from the Psychosocial Care Center. Visual sensitivity was compared between both SCZ groups and the SC group. Patients with SCZ who were chronic tobacco users presented lower visual sensitivity for chromatic (p < 0.001) and achromatic (p < 0.001) stimuli compared with the other groups. Our findings highlight the need to evaluate possible addictive behavior in patients with SCZ, which may contribute to public policies that seek to improve the quality of life of SCZ patients and their families.

Effects of smoking and smoking abstinence on spatial vision in chronic heavy smokers

Cigarette smoke is a complex chemical mixture, involving health-damaging components such as carbon monoxide, ammonia, pyridine, toluene and nicotine. While cognitive functions have been well documented in heavy smokers, spatial vision has been less characterized. In the article, we investigated smoking effects through contrast sensitivity function (CSF), a rigorous procedure that measures the spatial vision. Data were recorded from 48 participants, a group of non-smokers (n = 16), a group of chronic and heavy cigarette smokers (n = 16) and deprived smokers (n = 16); age range 20-45 years. Sinewave gratings with spatial frequencies ranging from 0.25 to 20 cycles per degree were used. All subjects were free from any neurological disorder, identifiable ocular disease and had normal acuity. No abnormalities were detected in the fundoscopic examination and in the optical coherence tomography exam. Contrary to expectations, performance on CSF differed between groups. Both smokers and deprived smokers presented a loss of contrast sensitivity compared to non-smokers. Post-hoc analyses suggest that deprived smokers were less sensitive at all spatial frequencies. These results suggest that not only chronic exposure to cigarette compounds but also withdrawal from nicotine affected spatial vision. This highlights the importance of understanding diffuse effects of smoking compounds on visual spatial processing.

Comparison of color discrimination in chronic heavy smokers and healthy subjects

Background: Cigarette smoke is probably the most significant source of exposure to toxic chemicals for humans, involving health-damaging components, such as nicotine, hydrogen cyanide and formaldehyde. The aim of the present study was to assess the influence of chronic heavy smoking on color discrimination (CD). Methods: All subjects were free of any neuropsychiatric disorder, identifiable ocular disease and had normal acuity. No abnormalities were detected in the fundoscopic examination and in the optical coherence tomography exam. We assessed color vision for healthy heavy smokers ( n = 15; age range, 20-45 years), deprived smokers ( n = 15, age range 20-45 years) and healthy non-smokers ( n = 15; age range, 20-45 years), using the psychophysical forced-choice method. All groups were matched for gender and education level. In this test, the volunteers had to choose the pseudoisochromatic stimulus containing a test frequency at four directions (e.g., up, down, right and left) in the subtest of Cambridge Colour Test (CCT): Trivector. Results: Performance on CCT differed between groups, and the observed pattern was that smokers had lower discrimination compared to non-smokers. In addition, deprived smokers presented lower discrimination to smokers and non-smokers. Contrary to expectation, the largest differences were observed for medium and long wavelengths. Conclusions: These results suggests that cigarette smoking, chronic exposure to its compounds, and withdrawal from nicotine affect color discrimination. This highlights the importance of understanding the diverse effects of nicotine on attentional bias.

Spatial and temporal aspects of visual backward masking in children and young adolescents

The development of visual functions is very diverse. Some visual functions mature within the first year of life, whereas maturation for other functions extends into adolescence. The reasons for these developmental differences are largely unknown. Here, we investigated spatiotemporal processing in children (7–9 years, n = 15), young adolescents (11–13 years, n = 26), and adults (18–33 years, n = 24) using the shine-through visual backward-masking paradigm. We found that children had significantly longer vernier durations than either young adolescents or adults. However, children’s spatial and temporal processing of complex masks was very similar to that of young adolescents and adults. We suggest that spatiotemporal processing related to visual backward masking is already fully developed at age 7, whereas the attentional processes related to target enhancement only mature in young adolescence.

Does chronic nicotine consumption influence visual backward masking in schizophrenia and schizotypy?

Nicotine consumption is higher for people within the schizophrenia spectrum compared to controls. This observation supports the self-medication hypothesis, that nicotine relieves symptoms in, for example, schizophrenia patients. We tested whether performance in an endophenotype of schizophrenia (visual backward masking, VBM) is modulated by nicotine consumption in i) smoking and non-smoking schizophrenia patients, their first-degree relatives, and age-matched controls, ii) non-smoking and smoking university students, and iii) non-smoking, early and late onset nicotine smokers. Overall, our results confirmed that VBM deficits are an endophenotype of schizophrenia, i.e., deficits were highest in patients, followed by their relatives, students scoring high in Cognitive Disorganisation, and controls. Moreover, we found i) beneficial effects of chronic nicotine consumption on VBM performance, in particular with increasing age, and ii) little impact of clinical status alone or in interaction with nicotine consumption on VBM performance. Given the younger age of undergraduate students (up to 30 years) versus controls and patients (up to 66 years), we propose that age-dependent VBM deficits emerge when schizotypy effects are targeted in populations of a larger age range, but that nicotine consumption might counteract these deficits (supporting the self-medication hypothesis).

Meeting overview: Sensory perception and schizophrenia, Lausanne, Switzerland June 31-July 1, 2014

Schizophrenia is increasingly being viewed as a “whole brain” disorder with deficits affecting widespread cortical and subcortical networks. Within this context, studies of visual cortical function may be particularly important both because visual processing deficits directly affect social and occupational function and because these systems are well characterized at the basic science level, permitting informative translational research. This article summarizes a conference on visual processing dysfunction in schizophrenia held in Lausanne, Switzerland from June 30 to July 1, 2014 and introduces this special issue. Speakers focused on multiple aspects of visual dysfunction in schizophrenia using behavioral, neurophysiological and fMRI-based approaches.

Four main themes emerged. First was a focus on response disturbances within the early visual system, using paradigms such as sensory EEG and MEG-based responses. Second, behavioral deficits were noted in processing related to local interaction within visual regions, using paradigms such as Vernier acuity or contour integration. These deficits provided potential model systems to understand impaired connectivity within the brain in schizophrenia more generally.

Third, several visual measures were found to correlate highly with symptoms and/or neurocognitive processing. Deficits in contour integration, for example, correlated highly with conceptual disorganization, whereas perceptual instability correlated with delusion formation. These findings highlight links between perceptual-level disturbance and clinical manifestation. Finally, the potential involvement of specific neurotransmitter receptors, including N-methyl-D-aspartate (NMDA)-type glutamate receptors and alpha7 nicotinic receptors were discussed as potential etiological mechanisms. Overall, the meeting highlighted the contributions of visual pathway dysfunction to the etiopathogenesis of neurocognitive dysfunction in schizophrenia.